LBRX (LB Pharmaceuticals Inc) Short-Term Debt to Capital

Corporate company logo of LB Pharmaceuticals Inc (LBRX)

LB Pharmaceuticals Inc (LBRX) faces stringent FDA oversight and uncertainty stemming from its reliance on licensees. The business relies on the modernization of classic psychotropic formulas, expanding its influence through proven molecules. The share price retrospective on GURU.Markets shows the 0.01 metric, while the company remains vulnerable to logistical disruptions and geopolitical barriers when defending its international patents.

Ratio of Short-Term Indebtedness to Capital: LB Pharma (LBRX) for 09/12/2025 - 10/30/2026

Analytical breakdowns for LB Pharmaceuticals Inc

- stock quotes and analyst forecast:
Stock Price LB Pharma|LBRX - Fair Value Consensus
- business market valuation indicators:
Market Capitalization LB Pharmaceuticals, Inc.|LBRX - Enterprise Value
- book capitalization information:
Net Assets per Single Share LB Pharmaceuticals|LBRX - Accounting Value of Company|Market Value to Book Value Ratio lbpharma.us|LBRX - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital LB Pharmaceuticals Inc|LBRX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio LB Pharmaceuticals|LBRX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio LB Pharmaceuticals, Inc.|LBRX - Long-Term Liabilities|Company Short-Term Debt LB Pharmaceuticals|Quick Liquidity Indicator lbpharma.us
- company profitability and valuation multiples indicators:
LBRX - Company Net Income
Fundamental valuation:LBRX LB Pharma
Brand item of LB Pharmaceuticals, Inc.

Liquidity control is critical for the biotechnology company LB Pharmaceuticals Inc (LBRX) due to the high costs associated with clinical trials for schizophrenia drugs. This metric compares the volume of liabilities maturing within one year against total equity, revealing the dependence on short-term borrowing. Analyzing the short-term financial leverage ratio allows for an assessment of the issuer's ability to service debt without selling assets. A decrease in this ratio confirms the financial stability of R&D processes and the security of existing cash reserves.

Competitor analysis for LB Pharmaceuticals Inc

Short-Term Debt to Capital ALKS|AVDL (Avadel Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ATAI (Atai Life Sciences N.V.)|Short-Term Debt to Capital ghres.com GHRS|MNMD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CMPS (COMPASS Pathways PLC)|Bright Minds Biosciences Inc (DRUG) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Vanda|CYBN (Cybin Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital altoneuroscience.com|Short-Term Debt to Equity Ratio NRXP (NRx Pharmaceuticals, Inc.)|CING (cingulate.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Silo Pharma SILO|CPHI (China Pharma Holdings Inc.) - Current Liabilities to Equity|CMND - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient pacificbayminerals.com PBM|SPRC (SciSparc) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital Seelos Therapeutics Inc. (SEEL)|VRPX (Virpax Pharmaceuticals Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Karuna Pharma (KRTX)